Delcath Systems, Inc. (DCTH) Stock

Understand Delcath Systems, Inc.: how it makes money

Delcath Systems makes and sells the HEPZATO Kit, a melphalan for injection system designed to deliver high-dose chemotherapy to the liver for treatment of primary and metastatic liver cancers, and it also generates product revenue from related kit and chemo-delivery products.

Delcath's commercial profit engine depends on converting the number of active, treating oncology centers into repeatable kit and product revenue (for example, HEPZATO kit revenue tied to active treatment centers and treating site activity), while clinical trial progress is a separate driver of future product opportunity.

Business quality (Weak): Latest-quarter reporting shows revenue of 0.0B, with operating margin still negative, so the near-term business is hard to gauge from top-line alone. The most actionable visibility in the provided data is the network of active treatment centers and kit/product revenue figures that move with that commercial adoption.

Valuation: At 1172× earnings, DCTH trades 3523% above the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

• Center network exists and is measurable: The company reports Active Treatment Centers of 28, and Active U.S. Treatment Centers of 29, which supports ongoing commercialization activity.
• Some product revenue is indicated even in a small-reported-revenue quarter: The provided segment revenue candidates show Auto Kit Revenue of 0.02B and HEPZATO Kit Revenue of 0.01B.
• Cost structure shows high gross margin in the latest quarter: Gross margin is reported at 85.1% for the period ending 2026-03-31, which can help absorb operating expense when utilization improves.

Bear case

• Profitability remains negative: Operating margin is reported at -6.5% for the period ending 2026-03-31.
• Near-term revenue scale appears very small or not captured in the reported total: Total revenue is reported as 0.0B for the period ending 2026-03-31, indicating limited observable earnings power in the latest quarter.
• Referral and treatment capacity metrics suggest potential pipeline bottlenecks: Centers Accepting Patient Referrals is 11, versus Active Treatment Centers of 28, which implies not all active centers are at the same referral and conversion stage.
• Clinical development adds uncertainty: The HEPZATO development program includes the FOCUS clinical trial for metastatic uveal melanoma, and clinical progress is not proven by the provided facts for near-term commercial outcomes.

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

• OrthoPediatrics Corp. (KIDS)
• AngioDynamics, Inc. (ANGO)
• MiMedx Group, Inc. (MDXG)
• Cerus Corporation (CERS)
• Tactile Systems Technology, Inc. (TCMD)
• NeuroPace, Inc. (NPCE)
• ClearPoint Neuro, Inc. (CLPT)
• Sight Sciences, Inc. (SGHT)